Patents by Inventor Boaz Amit

Boaz Amit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170196986
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 13, 2017
    Applicant: HEPACORE LTD.
    Inventors: Avner YAYON, Roy SIRKIS, Boaz AMIT, Avraham WORTZEL
  • Patent number: 9610357
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: April 4, 2017
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20140038892
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • Publication number: 20140005141
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicants: Bio-Technology General (Israel) Ltd., Prochon Biotech Ltd.
    Inventors: Boaz AMIT, Avraham Wortzel, Avner YAYON
  • Patent number: 8524885
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 3, 2013
    Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8329870
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Grant
    Filed: January 6, 2008
    Date of Patent: December 11, 2012
    Assignee: Hepacore Ltd.
    Inventors: Boaz Amit, Hilla Barkay-Olami, Avner Yayon
  • Publication number: 20100086594
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Application
    Filed: January 6, 2008
    Publication date: April 8, 2010
    Inventors: Boaz Amit, Hilla Barkay-Olami, Avner Yayon
  • Publication number: 20090149419
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: March 6, 2007
    Publication date: June 11, 2009
    Applicants: PROCHON BIOTECH LTD., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20050152906
    Abstract: The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The, present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 14, 2005
    Inventors: Avigdor Levanon, Tikva Vogel, Daniel Plaksin, Tuvia Peretz, Boaz Amit, Lena Cooperman, Yocheved Hagay, Esther Szanton, Yariv Kanfi, Rachel Ben-Levy, Tali Szrajber
  • Publication number: 20040001839
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits
  • Publication number: 20040002450
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Janette Lazarovits, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Ham, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Avigdor Levanon
  • Publication number: 20040001822
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Esther Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits